Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01FUC
|
|||
| Former ID |
DIB014573
|
|||
| Drug Name |
Exatecan
|
|||
| Synonyms |
Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1] | |
| Company |
Daiichi Seiyaku Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22FN3O4
|
|||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
|
|||
| InChI |
1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
|
|||
| InChIKey |
ZVYVPGLRVWUPMP-FYSMJZIKSA-N
|
|||
| CAS Number |
CAS 171335-80-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:135709
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00023972) Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.